These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 9728331

  • 21. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S, Baumann U.
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
    van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ.
    Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
    [Abstract] [Full Text] [Related]

  • 25. Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.
    Ward JP, Dunster JL, Derks G, Mistry P, Salazar JD.
    Math Med Biol; 2017 Sep 01; 34(3):335-390. PubMed ID: 27305933
    [Abstract] [Full Text] [Related]

  • 26. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G, Malvagia S, Materazzi S, Della Bona ML, Boenzi S, Martinelli D, Dionisi-Vici C.
    Anal Chem; 2012 Jan 17; 84(2):1184-8. PubMed ID: 22148291
    [Abstract] [Full Text] [Related]

  • 27. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
    McKiernan PJ.
    Drugs; 2006 Jan 17; 66(6):743-50. PubMed ID: 16706549
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Mitchell GA.
    Hum Exp Toxicol; 1996 Feb 17; 15(2):179-81. PubMed ID: 8645506
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
    Joshi SN, Venugopalan P.
    Ann Trop Paediatr; 2004 Sep 17; 24(3):259-65. PubMed ID: 15479577
    [Abstract] [Full Text] [Related]

  • 34. Hereditary tyrosinaemia type I: from basics to progress in treatment.
    Pitkänen ST, Salo MK, Heikinheimo M.
    Ann Med; 2000 Nov 17; 32(8):530-8. PubMed ID: 11127930
    [Abstract] [Full Text] [Related]

  • 35. Nontransplant treatment of tyrosinemia.
    Holme E, Lindstedt S.
    Clin Liver Dis; 2000 Nov 17; 4(4):805-14. PubMed ID: 11232358
    [Abstract] [Full Text] [Related]

  • 36. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I.
    Crone J, Möslinger D, Bodamer OA, Schima W, Huber WD, Holme E, Stöckler Ipsiroglu S.
    Acta Paediatr; 2003 May 17; 92(5):625-8. PubMed ID: 12839296
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.